Dark Knight
Well-Known Member
- Joined
- Sep 3, 2004
- Messages
- 21,649
- Reaction score
- 82
LONDON (AFP) Researchers at the University of Cambridge said Thursday they have found that a drug originally developed to treat leukemia can halt and even reverse the debilitating effects of multiple sclerosis (MS).
In trials, alemtuzumab reduced the number of attacks in sufferers and also helped them recover lost functions, apparently allowing damaged brain tissue to repair so that individuals were less disabled than at the start of the study.
"The ability of an MS drug to promote brain repair is unprecedented," said Dr Alasdair Coles, a lecturer at Cambridge university's department of clinical neurosciences, who coordinated many aspects of the study.
"We are witnessing a drug which, if given early enough, might effectively stop the advancement of the disease and also restore lost function by promoting repair of the damaged brain tissue."
The MS Society, Britain's largest support charity for those affected by the condition, said it was "delighted" at the trial's results, which must be followed up with more research before the drug can be licensed.
http://news.yahoo.com/s/afp/20081023/ts_afp/britainscienceresearch;_ylt=AoBJHaHDU02Gm_IkcAs8Wbus0NUE
In trials, alemtuzumab reduced the number of attacks in sufferers and also helped them recover lost functions, apparently allowing damaged brain tissue to repair so that individuals were less disabled than at the start of the study.
"The ability of an MS drug to promote brain repair is unprecedented," said Dr Alasdair Coles, a lecturer at Cambridge university's department of clinical neurosciences, who coordinated many aspects of the study.
"We are witnessing a drug which, if given early enough, might effectively stop the advancement of the disease and also restore lost function by promoting repair of the damaged brain tissue."
The MS Society, Britain's largest support charity for those affected by the condition, said it was "delighted" at the trial's results, which must be followed up with more research before the drug can be licensed.
http://news.yahoo.com/s/afp/20081023/ts_afp/britainscienceresearch;_ylt=AoBJHaHDU02Gm_IkcAs8Wbus0NUE